UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (36446) 36446
Newspaper Article (7804) 7804
Book Chapter (655) 655
Newsletter (582) 582
Magazine Article (450) 450
Government Document (228) 228
Trade Publication Article (155) 155
Book / eBook (59) 59
Report (43) 43
Transcript (39) 39
Reference (15) 15
Web Resource (14) 14
Conference Proceeding (12) 12
Book Review (5) 5
Dissertation (5) 5
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (30827) 30827
science & technology (29323) 29323
life sciences & biomedicine (28639) 28639
female (15856) 15856
male (15247) 15247
middle aged (12168) 12168
adult (11290) 11290
pharmacology & pharmacy (9905) 9905
clinical trials (9630) 9630
aged (9092) 9092
drug therapy (8822) 8822
treatment outcome (8465) 8465
drug dosages (7268) 7268
oncology (7141) 7141
animals (6087) 6087
care and treatment (5536) 5536
research (5369) 5369
patients (4967) 4967
double-blind method (4927) 4927
medicine & public health (4528) 4528
pharmaceutical industry (4210) 4210
studies (4178) 4178
cancer (4145) 4145
health aspects (3676) 3676
adolescent (3635) 3635
abridged index medicus (3382) 3382
dose-response relationship, drug (3373) 3373
drugs (3296) 3296
young adult (3259) 3259
analysis (3231) 3231
chemotherapy (3067) 3067
medical research (3061) 3061
dosage and administration (3045) 3045
pharmacology/toxicology (3014) 3014
fda approval (3008) 3008
antineoplastic agents - therapeutic use (2820) 2820
aged, 80 and over (2809) 2809
clinical trials as topic (2528) 2528
pharmacology (2442) 2442
drug administration schedule (2428) 2428
cancer therapies (2228) 2228
pharmacokinetics (2219) 2219
drug therapy, combination (2205) 2205
risk factors (2197) 2197
antineoplastic combined chemotherapy protocols - therapeutic use (2170) 2170
antineoplastic agents - adverse effects (2132) 2132
time factors (2094) 2094
medicine (2087) 2087
internal medicine (2086) 2086
neurosciences & neurology (2008) 2008
general & internal medicine (2003) 2003
immunology (1946) 1946
child (1897) 1897
tumors (1878) 1878
neoplasms - drug therapy (1856) 1856
complications and side effects (1824) 1824
hematology (1821) 1821
prospective studies (1821) 1821
administration, oral (1819) 1819
product development (1804) 1804
medicine, experimental (1771) 1771
medicine, general & internal (1768) 1768
united states (1740) 1740
safety (1704) 1704
metastasis (1681) 1681
clinical neurology (1672) 1672
usage (1666) 1666
quality of life (1658) 1658
medicine, research & experimental (1629) 1629
research & experimental medicine (1628) 1628
antineoplastic combined chemotherapy protocols - adverse effects (1502) 1502
pain (1492) 1492
diabetes (1490) 1490
review (1468) 1468
pediatrics (1447) 1447
research & development--r&d (1420) 1420
cardiovascular system & cardiology (1407) 1407
follow-up studies (1403) 1403
drugs, investigational - therapeutic use (1388) 1388
drug approval (1384) 1384
mortality (1382) 1382
prescription drugs (1365) 1365
surgery (1298) 1298
regulatory approval (1274) 1274
infectious diseases (1241) 1241
antineoplastic agents - administration & dosage (1228) 1228
pharmacotherapy (1227) 1227
breast cancer (1226) 1226
immunotherapy (1221) 1221
psychiatry (1209) 1209
infections (1204) 1204
cross-over studies (1201) 1201
neurosciences (1190) 1190
toxicity (1172) 1172
proteins (1165) 1165
randomized controlled trials as topic (1160) 1160
antineoplastic agents (1154) 1154
disease (1121) 1121
toxicology (1112) 1112
research article (1109) 1109
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (19) 19
Collection Dvlpm't (Acquisitions) - Vendor file (5) 5
UofT at Mississauga - Stacks (5) 5
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Humber River Regional Hospital - Finch Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
Markham Stouffville Hospital - Stacks (1) 1
Mt Sinai Hospital - Online (1) 1
New College (Ivey) - Stacks (1) 1
OISE - Stacks (1) 1
Online (1) 1
Online Resources - Online (1) 1
Online Resources - Stacks (1) 1
Robarts - Stacks (1) 1
UofT at Mississauga - Pharmacy (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (46396) 46396
German (85) 85
French (40) 40
Spanish (23) 23
Japanese (22) 22
Portuguese (20) 20
Russian (9) 9
Italian (8) 8
Norwegian (7) 7
Chinese (6) 6
Hungarian (4) 4
Swedish (4) 4
Danish (3) 3
Polish (3) 3
Dutch (2) 2
Czech (1) 1
Finnish (1) 1
Hebrew (1) 1
Persian (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Investigational new drugs, ISSN 1573-0646, 11/2018, Volume 37, Issue 4, pp. 666 - 673
Journal Article
Investigational new drugs, ISSN 1573-0646, 12/2013, Volume 32, Issue 3, pp. 489 - 499
...PHASE I STUDIES Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic... 
Novel antitumor agent | Medicine & Public Health | Aurora A kinase inhibitor | MLN8237 | Oncology | Cell cycle mechanisms of anticancer drug action | Pharmacology/Toxicology | Phase I-III Leukemia and lymphomas | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Protein Kinase Inhibitors - adverse effects | Aurora Kinase A - antagonists & inhibitors | Aurora Kinase A - metabolism | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Aurora Kinase A - genetics | Lymphoma, Non-Hodgkin - drug therapy | Protein Kinase Inhibitors - pharmacokinetics | Azepines - adverse effects | Neoplasm Recurrence, Local - metabolism | Pyrimidines - administration & dosage | Lymphoma, Non-Hodgkin - genetics | Multiple Myeloma - metabolism | Protein Kinase Inhibitors - administration & dosage | Maximum Tolerated Dose | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Lymphoma, Non-Hodgkin - metabolism | Pyrimidines - adverse effects | Pyrimidines - pharmacokinetics | Neoplasm Recurrence, Local - genetics | Aged | Azepines - pharmacokinetics | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Azepines - administration & dosage | Multiple Myeloma - genetics | Antimitotic agents | Complications and side effects | Chronic lymphocytic leukemia | Care and treatment | Dosage and administration | Genetic aspects | Research | Antineoplastic agents | Pharmacokinetics | Inhibitor drugs | Statistical analysis | Research & development--R&D | Clinical trials | Patients | Cancer therapies | Pharmaceuticals | Index Medicus | Phase I Studies
Journal Article
Diabetes technology & therapeutics, ISSN 1557-8593, 11/2011, Volume 13, Issue 11, pp. 1145 - 1154
Journal Article
Clinical and vaccine immunology, ISSN 1556-679X, 01/2014, Volume 21, Issue 1, pp. 56 - 65
Journal Article
Journal Article
Investigational new drugs, ISSN 0167-6997, 2/2017, Volume 35, Issue 1, pp. 47 - 58
Purpose TAK-733, an investigational, selective, allosteric MEK1/2 inhibitor, has demonstrated antitumor effects against multiple cancer cell lines and xenograft models... 
Solid tumor | Medicine & Public Health | TAK-733 | Oncology | Phase 1 | Pharmacology/Toxicology | MEK inhibition | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Extracellular Signal-Regulated MAP Kinases - blood | Skin Neoplasms - drug therapy | Colonic Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Colonic Neoplasms - metabolism | Young Adult | Antineoplastic Agents - adverse effects | Adult | Female | Pyrimidinones - pharmacology | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Uveal Neoplasms - metabolism | Phosphorylation - drug effects | Melanoma - metabolism | Protein Kinase Inhibitors - pharmacokinetics | MAP Kinase Kinase 1 - antagonists & inhibitors | Pyridones - pharmacokinetics | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Treatment Outcome | Uveal Neoplasms - drug therapy | Skin Neoplasms - metabolism | Maximum Tolerated Dose | Pyrimidinones - pharmacokinetics | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Aged | Protein Kinase Inhibitors - pharmacology | Pyridones - therapeutic use | Pyridones - adverse effects | Pyridones - pharmacology | Dose-response relationship (Biochemistry) | Care and treatment | Enzyme inhibitors | Patient outcomes | Dosage and administration | Methods | Cancer | Pharmaceutical industry | Index Medicus | Phase I Studies
Journal Article